-
Track & Monitor
NewCell & gene therapy in pharma: lentiviral vectors
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the pharma industry’s lentiviral vectors segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge.
-
Sector Analysis
NewBronchiectasis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033
Bronchiectasis Market Report Overview The Bronchiectasis market across the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and China) was valued at $1.4 billion in 2023 and the market will grow at a CAGR of more than 3% from 2023 to 2033. The 7MM (China, Japan, the United Kingdom, Spain, Italy, Germany, France, and the US). The market growth is attributed to the launch of brensocatib and an increase in the number of diagnosed prevalent cases of bronchiectasis. Bronchiectasis Market...
-
Sector Analysis
NewOsteoporosis Epidemiology Analysis and Forecast to 2033
Osteoporosis Report Overview In the 7MM, there were 20,291,551 diagnosed prevalent cases of osteoporosis in 2023. The diagnosed prevalent cases of osteoporosis will register an AGR of more than 1% during 2023-2033. Osteoporosis is a disease in which the density and quality of bone are reduced over time. In a normal process known as remodeling, some of a person’s bone cells dissolve (resorption) and new bone cells grow back (formation). For people with osteoporosis, bone loss outpaces the growth of...
-
Sector Analysis
NewFuture of Pharma – Looking Ahead to 2024
This report provides a summary of the near and long-term future of the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot and prioritize them within your sectors.
-
Thematic Analysis
NewPharma M&A Deals Q1 2024 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q1 2024 in the Pharma Sector
-
Sector Analysis
NewHER2-Positive Breast Cancer Epidemiology Analysis and Forecast to 2033
Reasons to buy the ‘HER2-Positive Breast Cancer Epidemiology’ market report: Get an overview of the HER2+ breast cancer risk factors, comorbidities, and global and historical epidemiological trends in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China). Get valuable insights into the 10-year epidemiology forecast for Diagnosed incident cases of all invasive breast cancer Diagnosed incident cases of HER2+ breast cancer Five diagnosed prevalent cases of HER2+ breast cancer Understand the diagnosed incident cases...
-
Sector Analysis
NewFriedreich Ataxia (FRDA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Friedreich Ataxia (FRDA) Marketed and Pipeline Drugs Report Overview Friedreich's Ataxia (FRDA) is a rare, genetic disorder. It is progressive and typically manifests between the ages of 10 and 15. The disorder is characterized by a gradual decline in coordination, muscle strength, and endurance. Individuals with FRDA often become reliant on wheelchairs as the condition advances. The Friedreich Ataxia (FRDA) marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast,...
-
Sector Analysis
NewPost-Operative Pain (POP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Post-Operative Pain (POP) Marketed and Pipeline Drugs Report Overview Post-operative pain (POP) is considered a form of acute pain due to surgical trauma with an inflammatory reaction and initiation of an afferent neuronal barrage. There could also be some generalized body pain before the operation with aggravation after the operation. This type of operation often needs complete or partial anesthesia. Disturbances in the channels and collaterals or the internal organs may be the cause. Key Mechanisms of Action (Marketed) · ...
-
Product Insights
NewMycosis Fungoides Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Mycosis Fungoides Clinical Trial Report Overview A total of 328 mycosis fungoides clinical trials were conducted as of April 2024. The mycosis fungoides clinical trial report provides a comprehensive understanding of the mycosis fungoides clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions · North America · ...
Testimonial
Your Drugs database is great, you can find all the information you want such as sales forecasts, countries, diseases, dates, clinical trials, and patent expiration. We are using this information to research the leading competitive products in our current project. In addition, we analyze the profiles of the leading products and use this information to set the differentiation profile of our own products and clarify our positioning. In terms of business forecasts, we are able to provide more objective figures by using the Drug Forecast and Market Analysis report series. The analysis of product share by disease (series of Drug Forecast and Market Analysis reports) is used for business feasibility assessment.”
The ability to evaluate or provide information on PJs in R&D from both product and disease perspectives (it is difficult to find a database that can be used comprehensively for both), stands GlobalData out from other providers. The release of new functions such as Likelihood of approval (LoA) analysis, which was something I wanted but did not exist, shows that GlobalData have done a good job of researching the industry and developing services from the customer’s perspective which is another positive.
GlobalData’s COVID-19 Bulletin, which is sent out several times a week, provides the latest information on COVID-19 related vaccines and therapeutics and is used as background information.
“GlobalData provides extensive and comprehensive Pharma and Biotech data along with spectacular customer support. I use their drug, trial and company data on a daily basis to support our sales and marketing efforts.”
“As a global biopharma R&D strategy consultancy, we use the GlobalData Pharma Intelligence platform across a broad spectrum of topics, it provides all key data in one place”